Global Oncology Biosimilars Market Research Report 2023(Status and Outlook)
Report Overview
Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
Bosson Research’s latest report provides a deep insight into the global Oncology Biosimilars market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oncology Biosimilars Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oncology Biosimilars market in any manner.
Global Oncology Biosimilars Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Market Segmentation (by Type)
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Market Segmentation (by Application)
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Oncology Biosimilars Market
Overview of the regional outlook of the Oncology Biosimilars Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oncology Biosimilars Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
Bosson Research’s latest report provides a deep insight into the global Oncology Biosimilars market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oncology Biosimilars Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oncology Biosimilars market in any manner.
Global Oncology Biosimilars Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Market Segmentation (by Type)
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Market Segmentation (by Application)
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Oncology Biosimilars Market
Overview of the regional outlook of the Oncology Biosimilars Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oncology Biosimilars Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Oncology Biosimilars
1.2 Key Market Segments
1.2.1 Oncology Biosimilars Segment by Type
1.2.2 Oncology Biosimilars Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ONCOLOGY BIOSIMILARS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Oncology Biosimilars Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Oncology Biosimilars Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ONCOLOGY BIOSIMILARS MARKET COMPETITIVE LANDSCAPE
3.1 Global Oncology Biosimilars Sales by Manufacturers (2018-2023)
3.2 Global Oncology Biosimilars Revenue Market Share by Manufacturers (2018-2023)
3.3 Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Oncology Biosimilars Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Oncology Biosimilars Sales Sites, Area Served, Product Type
3.6 Oncology Biosimilars Market Competitive Situation and Trends
3.6.1 Oncology Biosimilars Market Concentration Rate
3.6.2 Global 5 and 10 Largest Oncology Biosimilars Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ONCOLOGY BIOSIMILARS INDUSTRY CHAIN ANALYSIS
4.1 Oncology Biosimilars Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ONCOLOGY BIOSIMILARS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ONCOLOGY BIOSIMILARS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oncology Biosimilars Sales Market Share by Type (2018-2023)
6.3 Global Oncology Biosimilars Market Size Market Share by Type (2018-2023)
6.4 Global Oncology Biosimilars Price by Type (2018-2023)
7 ONCOLOGY BIOSIMILARS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oncology Biosimilars Market Sales by Application (2018-2023)
7.3 Global Oncology Biosimilars Market Size (M USD) by Application (2018-2023)
7.4 Global Oncology Biosimilars Sales Growth Rate by Application (2018-2023)
8 ONCOLOGY BIOSIMILARS MARKET SEGMENTATION BY REGION
8.1 Global Oncology Biosimilars Sales by Region
8.1.1 Global Oncology Biosimilars Sales by Region
8.1.2 Global Oncology Biosimilars Sales Market Share by Region
8.2 North America
8.2.1 North America Oncology Biosimilars Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Oncology Biosimilars Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Oncology Biosimilars Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Oncology Biosimilars Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Oncology Biosimilars Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Celltrion
9.1.1 Celltrion Oncology Biosimilars Basic Information
9.1.2 Celltrion Oncology Biosimilars Product Overview
9.1.3 Celltrion Oncology Biosimilars Product Market Performance
9.1.4 Celltrion Business Overview
9.1.5 Celltrion Oncology Biosimilars SWOT Analysis
9.1.6 Celltrion Recent Developments
9.2 Biocon
9.2.1 Biocon Oncology Biosimilars Basic Information
9.2.2 Biocon Oncology Biosimilars Product Overview
9.2.3 Biocon Oncology Biosimilars Product Market Performance
9.2.4 Biocon Business Overview
9.2.5 Biocon Oncology Biosimilars SWOT Analysis
9.2.6 Biocon Recent Developments
9.3 Dr. Reddy’s Laboratories
9.3.1 Dr. Reddy’s Laboratories Oncology Biosimilars Basic Information
9.3.2 Dr. Reddy’s Laboratories Oncology Biosimilars Product Overview
9.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Product Market Performance
9.3.4 Dr. Reddy’s Laboratories Business Overview
9.3.5 Dr. Reddy’s Laboratories Oncology Biosimilars SWOT Analysis
9.3.6 Dr. Reddy’s Laboratories Recent Developments
9.4 STADA Arzneimittel AG
9.4.1 STADA Arzneimittel AG Oncology Biosimilars Basic Information
9.4.2 STADA Arzneimittel AG Oncology Biosimilars Product Overview
9.4.3 STADA Arzneimittel AG Oncology Biosimilars Product Market Performance
9.4.4 STADA Arzneimittel AG Business Overview
9.4.5 STADA Arzneimittel AG Oncology Biosimilars SWOT Analysis
9.4.6 STADA Arzneimittel AG Recent Developments
9.5 Intas Pharmaceuticals
9.5.1 Intas Pharmaceuticals Oncology Biosimilars Basic Information
9.5.2 Intas Pharmaceuticals Oncology Biosimilars Product Overview
9.5.3 Intas Pharmaceuticals Oncology Biosimilars Product Market Performance
9.5.4 Intas Pharmaceuticals Business Overview
9.5.5 Intas Pharmaceuticals Oncology Biosimilars SWOT Analysis
9.5.6 Intas Pharmaceuticals Recent Developments
9.6 Pfizer
9.6.1 Pfizer Oncology Biosimilars Basic Information
9.6.2 Pfizer Oncology Biosimilars Product Overview
9.6.3 Pfizer Oncology Biosimilars Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Sandoz International
9.7.1 Sandoz International Oncology Biosimilars Basic Information
9.7.2 Sandoz International Oncology Biosimilars Product Overview
9.7.3 Sandoz International Oncology Biosimilars Product Market Performance
9.7.4 Sandoz International Business Overview
9.7.5 Sandoz International Recent Developments
9.8 Teva Pharmaceutical Industries Ltd
9.8.1 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Basic Information
9.8.2 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Overview
9.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Market Performance
9.8.4 Teva Pharmaceutical Industries Ltd Business Overview
9.8.5 Teva Pharmaceutical Industries Ltd Recent Developments
9.9 Apotex
9.9.1 Apotex Oncology Biosimilars Basic Information
9.9.2 Apotex Oncology Biosimilars Product Overview
9.9.3 Apotex Oncology Biosimilars Product Market Performance
9.9.4 Apotex Business Overview
9.9.5 Apotex Recent Developments
9.10 BIOCAD
9.10.1 BIOCAD Oncology Biosimilars Basic Information
9.10.2 BIOCAD Oncology Biosimilars Product Overview
9.10.3 BIOCAD Oncology Biosimilars Product Market Performance
9.10.4 BIOCAD Business Overview
9.10.5 BIOCAD Recent Developments
10 ONCOLOGY BIOSIMILARS MARKET FORECAST BY REGION
10.1 Global Oncology Biosimilars Market Size Forecast
10.2 Global Oncology Biosimilars Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Oncology Biosimilars Market Size Forecast by Country
10.2.3 Asia Pacific Oncology Biosimilars Market Size Forecast by Region
10.2.4 South America Oncology Biosimilars Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Oncology Biosimilars by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2024-2029)
11.1 Global Oncology Biosimilars Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Oncology Biosimilars by Type (2024-2029)
11.1.2 Global Oncology Biosimilars Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Oncology Biosimilars by Type (2024-2029)
11.2 Global Oncology Biosimilars Market Forecast by Application (2024-2029)
11.2.1 Global Oncology Biosimilars Sales (K MT) Forecast by Application
11.2.2 Global Oncology Biosimilars Market Size (M USD) Forecast by Application (2024-2029)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Oncology Biosimilars
1.2 Key Market Segments
1.2.1 Oncology Biosimilars Segment by Type
1.2.2 Oncology Biosimilars Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ONCOLOGY BIOSIMILARS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Oncology Biosimilars Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Oncology Biosimilars Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ONCOLOGY BIOSIMILARS MARKET COMPETITIVE LANDSCAPE
3.1 Global Oncology Biosimilars Sales by Manufacturers (2018-2023)
3.2 Global Oncology Biosimilars Revenue Market Share by Manufacturers (2018-2023)
3.3 Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Oncology Biosimilars Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Oncology Biosimilars Sales Sites, Area Served, Product Type
3.6 Oncology Biosimilars Market Competitive Situation and Trends
3.6.1 Oncology Biosimilars Market Concentration Rate
3.6.2 Global 5 and 10 Largest Oncology Biosimilars Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ONCOLOGY BIOSIMILARS INDUSTRY CHAIN ANALYSIS
4.1 Oncology Biosimilars Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ONCOLOGY BIOSIMILARS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ONCOLOGY BIOSIMILARS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oncology Biosimilars Sales Market Share by Type (2018-2023)
6.3 Global Oncology Biosimilars Market Size Market Share by Type (2018-2023)
6.4 Global Oncology Biosimilars Price by Type (2018-2023)
7 ONCOLOGY BIOSIMILARS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oncology Biosimilars Market Sales by Application (2018-2023)
7.3 Global Oncology Biosimilars Market Size (M USD) by Application (2018-2023)
7.4 Global Oncology Biosimilars Sales Growth Rate by Application (2018-2023)
8 ONCOLOGY BIOSIMILARS MARKET SEGMENTATION BY REGION
8.1 Global Oncology Biosimilars Sales by Region
8.1.1 Global Oncology Biosimilars Sales by Region
8.1.2 Global Oncology Biosimilars Sales Market Share by Region
8.2 North America
8.2.1 North America Oncology Biosimilars Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Oncology Biosimilars Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Oncology Biosimilars Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Oncology Biosimilars Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Oncology Biosimilars Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Celltrion
9.1.1 Celltrion Oncology Biosimilars Basic Information
9.1.2 Celltrion Oncology Biosimilars Product Overview
9.1.3 Celltrion Oncology Biosimilars Product Market Performance
9.1.4 Celltrion Business Overview
9.1.5 Celltrion Oncology Biosimilars SWOT Analysis
9.1.6 Celltrion Recent Developments
9.2 Biocon
9.2.1 Biocon Oncology Biosimilars Basic Information
9.2.2 Biocon Oncology Biosimilars Product Overview
9.2.3 Biocon Oncology Biosimilars Product Market Performance
9.2.4 Biocon Business Overview
9.2.5 Biocon Oncology Biosimilars SWOT Analysis
9.2.6 Biocon Recent Developments
9.3 Dr. Reddy’s Laboratories
9.3.1 Dr. Reddy’s Laboratories Oncology Biosimilars Basic Information
9.3.2 Dr. Reddy’s Laboratories Oncology Biosimilars Product Overview
9.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Product Market Performance
9.3.4 Dr. Reddy’s Laboratories Business Overview
9.3.5 Dr. Reddy’s Laboratories Oncology Biosimilars SWOT Analysis
9.3.6 Dr. Reddy’s Laboratories Recent Developments
9.4 STADA Arzneimittel AG
9.4.1 STADA Arzneimittel AG Oncology Biosimilars Basic Information
9.4.2 STADA Arzneimittel AG Oncology Biosimilars Product Overview
9.4.3 STADA Arzneimittel AG Oncology Biosimilars Product Market Performance
9.4.4 STADA Arzneimittel AG Business Overview
9.4.5 STADA Arzneimittel AG Oncology Biosimilars SWOT Analysis
9.4.6 STADA Arzneimittel AG Recent Developments
9.5 Intas Pharmaceuticals
9.5.1 Intas Pharmaceuticals Oncology Biosimilars Basic Information
9.5.2 Intas Pharmaceuticals Oncology Biosimilars Product Overview
9.5.3 Intas Pharmaceuticals Oncology Biosimilars Product Market Performance
9.5.4 Intas Pharmaceuticals Business Overview
9.5.5 Intas Pharmaceuticals Oncology Biosimilars SWOT Analysis
9.5.6 Intas Pharmaceuticals Recent Developments
9.6 Pfizer
9.6.1 Pfizer Oncology Biosimilars Basic Information
9.6.2 Pfizer Oncology Biosimilars Product Overview
9.6.3 Pfizer Oncology Biosimilars Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Sandoz International
9.7.1 Sandoz International Oncology Biosimilars Basic Information
9.7.2 Sandoz International Oncology Biosimilars Product Overview
9.7.3 Sandoz International Oncology Biosimilars Product Market Performance
9.7.4 Sandoz International Business Overview
9.7.5 Sandoz International Recent Developments
9.8 Teva Pharmaceutical Industries Ltd
9.8.1 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Basic Information
9.8.2 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Overview
9.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Market Performance
9.8.4 Teva Pharmaceutical Industries Ltd Business Overview
9.8.5 Teva Pharmaceutical Industries Ltd Recent Developments
9.9 Apotex
9.9.1 Apotex Oncology Biosimilars Basic Information
9.9.2 Apotex Oncology Biosimilars Product Overview
9.9.3 Apotex Oncology Biosimilars Product Market Performance
9.9.4 Apotex Business Overview
9.9.5 Apotex Recent Developments
9.10 BIOCAD
9.10.1 BIOCAD Oncology Biosimilars Basic Information
9.10.2 BIOCAD Oncology Biosimilars Product Overview
9.10.3 BIOCAD Oncology Biosimilars Product Market Performance
9.10.4 BIOCAD Business Overview
9.10.5 BIOCAD Recent Developments
10 ONCOLOGY BIOSIMILARS MARKET FORECAST BY REGION
10.1 Global Oncology Biosimilars Market Size Forecast
10.2 Global Oncology Biosimilars Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Oncology Biosimilars Market Size Forecast by Country
10.2.3 Asia Pacific Oncology Biosimilars Market Size Forecast by Region
10.2.4 South America Oncology Biosimilars Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Oncology Biosimilars by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2024-2029)
11.1 Global Oncology Biosimilars Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Oncology Biosimilars by Type (2024-2029)
11.1.2 Global Oncology Biosimilars Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Oncology Biosimilars by Type (2024-2029)
11.2 Global Oncology Biosimilars Market Forecast by Application (2024-2029)
11.2.1 Global Oncology Biosimilars Sales (K MT) Forecast by Application
11.2.2 Global Oncology Biosimilars Market Size (M USD) Forecast by Application (2024-2029)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Oncology Biosimilars Market Size Comparison by Region (M USD)
Table 5. Global Oncology Biosimilars Sales (K MT) by Manufacturers (2018-2023)
Table 6. Global Oncology Biosimilars Sales Market Share by Manufacturers (2018-2023)
Table 7. Global Oncology Biosimilars Revenue (M USD) by Manufacturers (2018-2023)
Table 8. Global Oncology Biosimilars Revenue Share by Manufacturers (2018-2023)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2022)
Table 10. Global Market Oncology Biosimilars Average Price (USD/MT) of Key Manufacturers (2018-2023)
Table 11. Manufacturers Oncology Biosimilars Sales Sites and Area Served
Table 12. Manufacturers Oncology Biosimilars Product Type
Table 13. Global Oncology Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Oncology Biosimilars
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oncology Biosimilars Market Challenges
Table 22. Market Restraints
Table 23. Global Oncology Biosimilars Sales by Type (K MT)
Table 24. Global Oncology Biosimilars Market Size by Type (M USD)
Table 25. Global Oncology Biosimilars Sales (K MT) by Type (2018-2023)
Table 26. Global Oncology Biosimilars Sales Market Share by Type (2018-2023)
Table 27. Global Oncology Biosimilars Market Size (M USD) by Type (2018-2023)
Table 28. Global Oncology Biosimilars Market Size Share by Type (2018-2023)
Table 29. Global Oncology Biosimilars Price (USD/MT) by Type (2018-2023)
Table 30. Global Oncology Biosimilars Sales (K MT) by Application
Table 31. Global Oncology Biosimilars Market Size by Application
Table 32. Global Oncology Biosimilars Sales by Application (2018-2023) & (K MT)
Table 33. Global Oncology Biosimilars Sales Market Share by Application (2018-2023)
Table 34. Global Oncology Biosimilars Sales by Application (2018-2023) & (M USD)
Table 35. Global Oncology Biosimilars Market Share by Application (2018-2023)
Table 36. Global Oncology Biosimilars Sales Growth Rate by Application (2018-2023)
Table 37. Global Oncology Biosimilars Sales by Region (2018-2023) & (K MT)
Table 38. Global Oncology Biosimilars Sales Market Share by Region (2018-2023)
Table 39. North America Oncology Biosimilars Sales by Country (2018-2023) & (K MT)
Table 40. Europe Oncology Biosimilars Sales by Country (2018-2023) & (K MT)
Table 41. Asia Pacific Oncology Biosimilars Sales by Region (2018-2023) & (K MT)
Table 42. South America Oncology Biosimilars Sales by Country (2018-2023) & (K MT)
Table 43. Middle East and Africa Oncology Biosimilars Sales by Region (2018-2023) & (K MT)
Table 44. Celltrion Oncology Biosimilars Basic Information
Table 45. Celltrion Oncology Biosimilars Product Overview
Table 46. Celltrion Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 47. Celltrion Business Overview
Table 48. Celltrion Oncology Biosimilars SWOT Analysis
Table 49. Celltrion Recent Developments
Table 50. Biocon Oncology Biosimilars Basic Information
Table 51. Biocon Oncology Biosimilars Product Overview
Table 52. Biocon Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 53. Biocon Business Overview
Table 54. Biocon Oncology Biosimilars SWOT Analysis
Table 55. Biocon Recent Developments
Table 56. Dr. Reddy’s Laboratories Oncology Biosimilars Basic Information
Table 57. Dr. Reddy’s Laboratories Oncology Biosimilars Product Overview
Table 58. Dr. Reddy’s Laboratories Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 59. Dr. Reddy’s Laboratories Business Overview
Table 60. Dr. Reddy’s Laboratories Oncology Biosimilars SWOT Analysis
Table 61. Dr. Reddy’s Laboratories Recent Developments
Table 62. STADA Arzneimittel AG Oncology Biosimilars Basic Information
Table 63. STADA Arzneimittel AG Oncology Biosimilars Product Overview
Table 64. STADA Arzneimittel AG Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 65. STADA Arzneimittel AG Business Overview
Table 66. STADA Arzneimittel AG Oncology Biosimilars SWOT Analysis
Table 67. STADA Arzneimittel AG Recent Developments
Table 68. Intas Pharmaceuticals Oncology Biosimilars Basic Information
Table 69. Intas Pharmaceuticals Oncology Biosimilars Product Overview
Table 70. Intas Pharmaceuticals Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 71. Intas Pharmaceuticals Business Overview
Table 72. Intas Pharmaceuticals Oncology Biosimilars SWOT Analysis
Table 73. Intas Pharmaceuticals Recent Developments
Table 74. Pfizer Oncology Biosimilars Basic Information
Table 75. Pfizer Oncology Biosimilars Product Overview
Table 76. Pfizer Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 77. Pfizer Business Overview
Table 78. Pfizer Recent Developments
Table 79. Sandoz International Oncology Biosimilars Basic Information
Table 80. Sandoz International Oncology Biosimilars Product Overview
Table 81. Sandoz International Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 82. Sandoz International Business Overview
Table 83. Sandoz International Recent Developments
Table 84. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Basic Information
Table 85. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Overview
Table 86. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 87. Teva Pharmaceutical Industries Ltd Business Overview
Table 88. Teva Pharmaceutical Industries Ltd Recent Developments
Table 89. Apotex Oncology Biosimilars Basic Information
Table 90. Apotex Oncology Biosimilars Product Overview
Table 91. Apotex Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 92. Apotex Business Overview
Table 93. Apotex Recent Developments
Table 94. BIOCAD Oncology Biosimilars Basic Information
Table 95. BIOCAD Oncology Biosimilars Product Overview
Table 96. BIOCAD Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 97. BIOCAD Business Overview
Table 98. BIOCAD Recent Developments
Table 99. Global Oncology Biosimilars Sales Forecast by Region (2024-2029) & (K MT)
Table 100. Global Oncology Biosimilars Market Size Forecast by Region (2024-2029) & (M USD)
Table 101. North America Oncology Biosimilars Sales Forecast by Country (2024-2029) & (K MT)
Table 102. North America Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 103. Europe Oncology Biosimilars Sales Forecast by Country (2024-2029) & (K MT)
Table 104. Europe Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 105. Asia Pacific Oncology Biosimilars Sales Forecast by Region (2024-2029) & (K MT)
Table 106. Asia Pacific Oncology Biosimilars Market Size Forecast by Region (2024-2029) & (M USD)
Table 107. South America Oncology Biosimilars Sales Forecast by Country (2024-2029) & (K MT)
Table 108. South America Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 109. Middle East and Africa Oncology Biosimilars Consumption Forecast by Country (2024-2029) & (Units)
Table 110. Middle East and Africa Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 111. Global Oncology Biosimilars Sales Forecast by Type (2024-2029) & (K MT)
Table 112. Global Oncology Biosimilars Market Size Forecast by Type (2024-2029) & (M USD)
Table 113. Global Oncology Biosimilars Price Forecast by Type (2024-2029) & (USD/MT)
Table 114. Global Oncology Biosimilars Sales (K MT) Forecast by Application (2024-2029)
Table 115. Global Oncology Biosimilars Market Size Forecast by Application (2024-2029) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Oncology Biosimilars Market Size Comparison by Region (M USD)
Table 5. Global Oncology Biosimilars Sales (K MT) by Manufacturers (2018-2023)
Table 6. Global Oncology Biosimilars Sales Market Share by Manufacturers (2018-2023)
Table 7. Global Oncology Biosimilars Revenue (M USD) by Manufacturers (2018-2023)
Table 8. Global Oncology Biosimilars Revenue Share by Manufacturers (2018-2023)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2022)
Table 10. Global Market Oncology Biosimilars Average Price (USD/MT) of Key Manufacturers (2018-2023)
Table 11. Manufacturers Oncology Biosimilars Sales Sites and Area Served
Table 12. Manufacturers Oncology Biosimilars Product Type
Table 13. Global Oncology Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Oncology Biosimilars
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oncology Biosimilars Market Challenges
Table 22. Market Restraints
Table 23. Global Oncology Biosimilars Sales by Type (K MT)
Table 24. Global Oncology Biosimilars Market Size by Type (M USD)
Table 25. Global Oncology Biosimilars Sales (K MT) by Type (2018-2023)
Table 26. Global Oncology Biosimilars Sales Market Share by Type (2018-2023)
Table 27. Global Oncology Biosimilars Market Size (M USD) by Type (2018-2023)
Table 28. Global Oncology Biosimilars Market Size Share by Type (2018-2023)
Table 29. Global Oncology Biosimilars Price (USD/MT) by Type (2018-2023)
Table 30. Global Oncology Biosimilars Sales (K MT) by Application
Table 31. Global Oncology Biosimilars Market Size by Application
Table 32. Global Oncology Biosimilars Sales by Application (2018-2023) & (K MT)
Table 33. Global Oncology Biosimilars Sales Market Share by Application (2018-2023)
Table 34. Global Oncology Biosimilars Sales by Application (2018-2023) & (M USD)
Table 35. Global Oncology Biosimilars Market Share by Application (2018-2023)
Table 36. Global Oncology Biosimilars Sales Growth Rate by Application (2018-2023)
Table 37. Global Oncology Biosimilars Sales by Region (2018-2023) & (K MT)
Table 38. Global Oncology Biosimilars Sales Market Share by Region (2018-2023)
Table 39. North America Oncology Biosimilars Sales by Country (2018-2023) & (K MT)
Table 40. Europe Oncology Biosimilars Sales by Country (2018-2023) & (K MT)
Table 41. Asia Pacific Oncology Biosimilars Sales by Region (2018-2023) & (K MT)
Table 42. South America Oncology Biosimilars Sales by Country (2018-2023) & (K MT)
Table 43. Middle East and Africa Oncology Biosimilars Sales by Region (2018-2023) & (K MT)
Table 44. Celltrion Oncology Biosimilars Basic Information
Table 45. Celltrion Oncology Biosimilars Product Overview
Table 46. Celltrion Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 47. Celltrion Business Overview
Table 48. Celltrion Oncology Biosimilars SWOT Analysis
Table 49. Celltrion Recent Developments
Table 50. Biocon Oncology Biosimilars Basic Information
Table 51. Biocon Oncology Biosimilars Product Overview
Table 52. Biocon Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 53. Biocon Business Overview
Table 54. Biocon Oncology Biosimilars SWOT Analysis
Table 55. Biocon Recent Developments
Table 56. Dr. Reddy’s Laboratories Oncology Biosimilars Basic Information
Table 57. Dr. Reddy’s Laboratories Oncology Biosimilars Product Overview
Table 58. Dr. Reddy’s Laboratories Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 59. Dr. Reddy’s Laboratories Business Overview
Table 60. Dr. Reddy’s Laboratories Oncology Biosimilars SWOT Analysis
Table 61. Dr. Reddy’s Laboratories Recent Developments
Table 62. STADA Arzneimittel AG Oncology Biosimilars Basic Information
Table 63. STADA Arzneimittel AG Oncology Biosimilars Product Overview
Table 64. STADA Arzneimittel AG Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 65. STADA Arzneimittel AG Business Overview
Table 66. STADA Arzneimittel AG Oncology Biosimilars SWOT Analysis
Table 67. STADA Arzneimittel AG Recent Developments
Table 68. Intas Pharmaceuticals Oncology Biosimilars Basic Information
Table 69. Intas Pharmaceuticals Oncology Biosimilars Product Overview
Table 70. Intas Pharmaceuticals Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 71. Intas Pharmaceuticals Business Overview
Table 72. Intas Pharmaceuticals Oncology Biosimilars SWOT Analysis
Table 73. Intas Pharmaceuticals Recent Developments
Table 74. Pfizer Oncology Biosimilars Basic Information
Table 75. Pfizer Oncology Biosimilars Product Overview
Table 76. Pfizer Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 77. Pfizer Business Overview
Table 78. Pfizer Recent Developments
Table 79. Sandoz International Oncology Biosimilars Basic Information
Table 80. Sandoz International Oncology Biosimilars Product Overview
Table 81. Sandoz International Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 82. Sandoz International Business Overview
Table 83. Sandoz International Recent Developments
Table 84. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Basic Information
Table 85. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Overview
Table 86. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 87. Teva Pharmaceutical Industries Ltd Business Overview
Table 88. Teva Pharmaceutical Industries Ltd Recent Developments
Table 89. Apotex Oncology Biosimilars Basic Information
Table 90. Apotex Oncology Biosimilars Product Overview
Table 91. Apotex Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 92. Apotex Business Overview
Table 93. Apotex Recent Developments
Table 94. BIOCAD Oncology Biosimilars Basic Information
Table 95. BIOCAD Oncology Biosimilars Product Overview
Table 96. BIOCAD Oncology Biosimilars Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 97. BIOCAD Business Overview
Table 98. BIOCAD Recent Developments
Table 99. Global Oncology Biosimilars Sales Forecast by Region (2024-2029) & (K MT)
Table 100. Global Oncology Biosimilars Market Size Forecast by Region (2024-2029) & (M USD)
Table 101. North America Oncology Biosimilars Sales Forecast by Country (2024-2029) & (K MT)
Table 102. North America Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 103. Europe Oncology Biosimilars Sales Forecast by Country (2024-2029) & (K MT)
Table 104. Europe Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 105. Asia Pacific Oncology Biosimilars Sales Forecast by Region (2024-2029) & (K MT)
Table 106. Asia Pacific Oncology Biosimilars Market Size Forecast by Region (2024-2029) & (M USD)
Table 107. South America Oncology Biosimilars Sales Forecast by Country (2024-2029) & (K MT)
Table 108. South America Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 109. Middle East and Africa Oncology Biosimilars Consumption Forecast by Country (2024-2029) & (Units)
Table 110. Middle East and Africa Oncology Biosimilars Market Size Forecast by Country (2024-2029) & (M USD)
Table 111. Global Oncology Biosimilars Sales Forecast by Type (2024-2029) & (K MT)
Table 112. Global Oncology Biosimilars Market Size Forecast by Type (2024-2029) & (M USD)
Table 113. Global Oncology Biosimilars Price Forecast by Type (2024-2029) & (USD/MT)
Table 114. Global Oncology Biosimilars Sales (K MT) Forecast by Application (2024-2029)
Table 115. Global Oncology Biosimilars Market Size Forecast by Application (2024-2029) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Oncology Biosimilars
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oncology Biosimilars Market Size (M USD), 2018-2029
Figure 5. Global Oncology Biosimilars Market Size (M USD) (2018-2029)
Figure 6. Global Oncology Biosimilars Sales (K MT) & (2018-2029)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oncology Biosimilars Market Size by Country (M USD)
Figure 11. Oncology Biosimilars Sales Share by Manufacturers in 2022
Figure 12. Global Oncology Biosimilars Revenue Share by Manufacturers in 2022
Figure 13. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 Vs 2022
Figure 14. Global Market Oncology Biosimilars Average Price (USD/MT) of Key Manufacturers in 2022
Figure 15. The Global 5 and 10 Largest Players: Market Share by Oncology Biosimilars Revenue in 2022
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Oncology Biosimilars Market Share by Type
Figure 18. Sales Market Share of Oncology Biosimilars by Type (2018-2023)
Figure 19. Sales Market Share of Oncology Biosimilars by Type in 2022
Figure 20. Market Size Share of Oncology Biosimilars by Type (2018-2023)
Figure 21. Market Size Market Share of Oncology Biosimilars by Type in 2022
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Oncology Biosimilars Market Share by Application
Figure 24. Global Oncology Biosimilars Sales Market Share by Application (2018-2023)
Figure 25. Global Oncology Biosimilars Sales Market Share by Application in 2022
Figure 26. Global Oncology Biosimilars Market Share by Application (2018-2023)
Figure 27. Global Oncology Biosimilars Market Share by Application in 2022
Figure 28. Global Oncology Biosimilars Sales Growth Rate by Application (2018-2023)
Figure 29. Global Oncology Biosimilars Sales Market Share by Region (2018-2023)
Figure 30. North America Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 31. North America Oncology Biosimilars Sales Market Share by Country in 2022
Figure 32. U.S. Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 33. Canada Oncology Biosimilars Sales (K MT) and Growth Rate (2018-2023)
Figure 34. Mexico Oncology Biosimilars Sales (Units) and Growth Rate (2018-2023)
Figure 35. Europe Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 36. Europe Oncology Biosimilars Sales Market Share by Country in 2022
Figure 37. Germany Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 38. France Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 39. U.K. Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 40. Italy Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 41. Russia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 42. Asia Pacific Oncology Biosimilars Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Oncology Biosimilars Sales Market Share by Region in 2022
Figure 44. China Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 45. Japan Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 46. South Korea Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 47. India Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 48. Southeast Asia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 49. South America Oncology Biosimilars Sales and Growth Rate (K MT)
Figure 50. South America Oncology Biosimilars Sales Market Share by Country in 2022
Figure 51. Brazil Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 52. Argentina Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 53. Columbia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 54. Middle East and Africa Oncology Biosimilars Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Oncology Biosimilars Sales Market Share by Region in 2022
Figure 56. Saudi Arabia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 57. UAE Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 58. Egypt Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 59. Nigeria Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 60. South Africa Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 61. Global Oncology Biosimilars Sales Forecast by Volume (2018-2029) & (K MT)
Figure 62. Global Oncology Biosimilars Market Size Forecast by Value (2018-2029) & (M USD)
Figure 63. Global Oncology Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 64. Global Oncology Biosimilars Market Share Forecast by Type (2024-2029)
Figure 65. Global Oncology Biosimilars Sales Forecast by Application (2024-2029)
Figure 66. Global Oncology Biosimilars Market Share Forecast by Application (2024-2029)
Figure 1. Product Picture of Oncology Biosimilars
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oncology Biosimilars Market Size (M USD), 2018-2029
Figure 5. Global Oncology Biosimilars Market Size (M USD) (2018-2029)
Figure 6. Global Oncology Biosimilars Sales (K MT) & (2018-2029)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oncology Biosimilars Market Size by Country (M USD)
Figure 11. Oncology Biosimilars Sales Share by Manufacturers in 2022
Figure 12. Global Oncology Biosimilars Revenue Share by Manufacturers in 2022
Figure 13. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 Vs 2022
Figure 14. Global Market Oncology Biosimilars Average Price (USD/MT) of Key Manufacturers in 2022
Figure 15. The Global 5 and 10 Largest Players: Market Share by Oncology Biosimilars Revenue in 2022
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Oncology Biosimilars Market Share by Type
Figure 18. Sales Market Share of Oncology Biosimilars by Type (2018-2023)
Figure 19. Sales Market Share of Oncology Biosimilars by Type in 2022
Figure 20. Market Size Share of Oncology Biosimilars by Type (2018-2023)
Figure 21. Market Size Market Share of Oncology Biosimilars by Type in 2022
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Oncology Biosimilars Market Share by Application
Figure 24. Global Oncology Biosimilars Sales Market Share by Application (2018-2023)
Figure 25. Global Oncology Biosimilars Sales Market Share by Application in 2022
Figure 26. Global Oncology Biosimilars Market Share by Application (2018-2023)
Figure 27. Global Oncology Biosimilars Market Share by Application in 2022
Figure 28. Global Oncology Biosimilars Sales Growth Rate by Application (2018-2023)
Figure 29. Global Oncology Biosimilars Sales Market Share by Region (2018-2023)
Figure 30. North America Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 31. North America Oncology Biosimilars Sales Market Share by Country in 2022
Figure 32. U.S. Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 33. Canada Oncology Biosimilars Sales (K MT) and Growth Rate (2018-2023)
Figure 34. Mexico Oncology Biosimilars Sales (Units) and Growth Rate (2018-2023)
Figure 35. Europe Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 36. Europe Oncology Biosimilars Sales Market Share by Country in 2022
Figure 37. Germany Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 38. France Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 39. U.K. Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 40. Italy Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 41. Russia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 42. Asia Pacific Oncology Biosimilars Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Oncology Biosimilars Sales Market Share by Region in 2022
Figure 44. China Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 45. Japan Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 46. South Korea Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 47. India Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 48. Southeast Asia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 49. South America Oncology Biosimilars Sales and Growth Rate (K MT)
Figure 50. South America Oncology Biosimilars Sales Market Share by Country in 2022
Figure 51. Brazil Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 52. Argentina Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 53. Columbia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 54. Middle East and Africa Oncology Biosimilars Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Oncology Biosimilars Sales Market Share by Region in 2022
Figure 56. Saudi Arabia Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 57. UAE Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 58. Egypt Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 59. Nigeria Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 60. South Africa Oncology Biosimilars Sales and Growth Rate (2018-2023) & (K MT)
Figure 61. Global Oncology Biosimilars Sales Forecast by Volume (2018-2029) & (K MT)
Figure 62. Global Oncology Biosimilars Market Size Forecast by Value (2018-2029) & (M USD)
Figure 63. Global Oncology Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 64. Global Oncology Biosimilars Market Share Forecast by Type (2024-2029)
Figure 65. Global Oncology Biosimilars Sales Forecast by Application (2024-2029)
Figure 66. Global Oncology Biosimilars Market Share Forecast by Application (2024-2029)
